Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 1626 • ACR Convergence 2021
Use of Total Hip Arthroplasty in Patients Under 21 Years Old: A U.S. Population Analysis
J. Alex Gibbons¹, Cynthia Kahlenberg¹, Deanna Jannat-Khah¹, Susan Goodman¹, Lisa Mandl¹, Peter Sculco¹, Stuart Goodman², Mark Figgie¹ and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Stanford University, Stanford, CA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Total hip arthroplasty (THA) is a treatment option for young patients with severe hip pathology due to congenital, developmental, rheumatologic, traumatic, and other acquired…
Abstract Number: 0243 • ACR Convergence 2021
Effectiveness of Abatacept in Patients with JIA, Classified by Category: Results from the PRCSG/PRINTO JIA Real-World Registry
Daniel Lovell¹, Nikolay Tzaribachev², Tracy Ting³, Ekaterina Alexeeva⁴, Teresa Giani⁵, Thomas Griffin⁶, John Bohnsack⁷, Andrew Zeft⁸, Richard Vehe⁹, Stacey Tarvin¹⁰, Gerd Horneff¹¹, Maria Trachana¹², Alyssa Dominique¹³, Lixian Dong¹³, Tzuyung Douglas Kou¹³, Robert Wong¹⁴, Alberto Martini¹⁵, Hermine Brunner³ and Nicolino Ruperto¹⁶, ¹Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ²PRI Research, Bad Bramstedt, Germany, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Scientific Center of Children Health of RAMS, Moscow, Russia, ⁵Università di Siena, Siena, Italy, ⁶Levine Children's Hospital, Charlotte, NC, ⁷University of Utah, Salt Lake City, UT, ⁸Cleveland Clinic, Cleveland, OH, ⁹University of Minnesota, Twin Cities, MN, ¹⁰Riley Hospital for Children at Indiana University, Indianapolis, IN, ¹¹Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, ¹²Aristotle University of Thessaloniki, Thessaloniki, Greece, ¹³Bristol Myers Squibb, Princeton, NJ, ¹⁴Bristol Myers Squibb, Basking Ridge, NJ, ¹⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁶IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Long-term treatment with abatacept, a selective T-cell co-stimulation modulator, is effective and well tolerated in patients with JIA.1–4 The objective of this analysis was…
Abstract Number: 0263 • ACR Convergence 2021
Patterns of Medication Switching in Juvenile Idiopathic Arthritis: A Retrospective Analysis of a National Administrative Claims Database
Mei-Sing Ong¹, Sarah Ringold², Melissa Mannion³, Marc Natter⁴, Laura Schanberg⁵ and Yukiko Kimura⁶, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Seattle Children's Hospital, Seattle, WA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston Children's Hospital, Boston, MA, ⁵Duke University Medical Center, Durham, NC, ⁶Hackensack University Medical Center, New York, NY
Background/Purpose: Although the increasing availability of biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has significantly improved outcomes for patients with Juvenile Idiopathic…
Abstract Number: 1631 • ACR Convergence 2021
Predictive Factors for Lack of Response to Treatment in a Long-term Cohort of Patients with Juvenile Idiopathic Arthritis-associated Uveitis
Francesca Minoia¹, Luca Marelli², Francesca Pregnolato³, Gisella Beatrice Beretta⁴, Chiara Mapelli⁴, Gaia Leone⁴, Gilberto Cincinelli³, Paolo Nucci⁵, Teresa Giani⁶, Elisabetta Miserocchi⁷ and Rolando Cimaz⁸, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ²Ospedale San Giuseppe, IRCCS Multimedica, Milan, Italy, ³Università degli Studi di Milano, Milan, Italy, ⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ⁵Ospedale San Giuseppe, IRCCS Multimedica, Università degli Studi di Milano, Milan, Italy, ⁶Università di Siena, Siena, Italy, ⁷San Raffaele Scientific Institute, Milan, Italy, ⁸ASST Gaetano Pini-CTO, Università degli Studi di Milano, Milan, Italy
Background/Purpose: Uveitis is the main extraarticular complication of juvenile idiopathic arthritis (JIA) with still a significant impact on JIA morbidity, despite continuous improvement in systemic…
Abstract Number: 0245 • ACR Convergence 2021
Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry
Hermine Brunner¹, Daniel Lovell², Michael Henrickson¹, Ruy Carrassco³, Kirsten Minden⁴, Lyudmila Grebenkina⁵, James Nocton⁶, Ingrid Louw⁷, Linda Wagner-Weiner⁸, Gabriel Vega Cornejo⁹, Sylvia Kamphuis¹⁰, Vyacheslav Chasnyk¹¹, Heather Walters¹², Simone Appenzeller¹³, Jordi Anton¹⁴, Alyssa Dominique¹⁵, Robert Wong¹⁶, Lixian Dong¹⁵, Tzuyung Douglas Kou¹⁵, Alberto Martini¹⁷ and Nicolino Ruperto¹⁸, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ³Presbyterian Health Services, Albuquerque, NM, ⁴Charite University Hospital Berlin, Berlin, Germany, ⁵Togliatti City Clinical Hospital №5, Togliatti, Russia, ⁶Medical College of Wisconsin, Milwaukee, WI, ⁷Panorama Medical Centre, Cape Town, South Africa, ⁸University of Chicago (Comer Children's), Chicago, IL, ⁹Crea de Guadalajara/Hospital México Americano, Guadalajara, Mexico, ¹⁰Sophia Children’s Hospital, Erasmus University Medical Center, Rotterdam, Netherlands, ¹¹Saint-Petersburg State Pediatric Medical Academy, Saint Petersburg, Russia, ¹²Cohen Children's Hospital, New York, NY, ¹³Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ¹⁴Hospital Sant Joan de Deu, University of Barcelona, Barcelona, Spain, ¹⁵Bristol Myers Squibb, Princeton, NJ, ¹⁶Bristol Myers Squibb, Basking Ridge, NJ, ¹⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁸IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Abatacept (ABA) is well tolerated and effective in patients with JIA.1 The Pediatric Rheumatology Collaborative Study Group (PRCSG)/ Paediatric Rheumatology INternational Trials Organisation (PRINTO)…
Abstract Number: 0264 • ACR Convergence 2021
Joint Acoustic Emissions as a Biomarker to Differentiate Between Active and Inactive Juvenile Idiopathic Arthritis via 2-stage Machine Learning Classifier
Luis Rosa¹, Sevda Gharehbaghi¹, Omer Inan¹, Daniel Whittingslow², Lori Ponder³ and Sampath Prahalad⁴, ¹Georgia Institute of Technology, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most prevalent chronic rheumatic disease and can result in disability in children. JIA most commonly affects the knee.…
Abstract Number: 1639 • ACR Convergence 2021
A Comparison of Cardiovascular Health Indicators in Children with Juvenile Idiopathic Arthritis Who Meet and Do Not Meet the Physical Activity Guidelines
Madelyn Byra¹, Nicole Proudfoot², Si Ru Chen¹, Maureen MacDonald³, Tania Cellucci⁴, Michelle Batthish⁵, Brian Timmons⁶ and Joyce Obeid⁶, ¹Child Health & Exercise Medicine Program, McMaster University, Hamilton, ON, Canada, ²Child Health & Exercise Medicine Program, McMaster University; Department of Kinesiology, McMaster University, Hamilton, ON, Canada, ³Department of Kinesiology, McMaster University, Hamilton, ON, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Child Health & Exercise Medicine Program, McMaster University; Department of Pediatrics, McMaster University, Hamilton, ON, Canada
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) engage in less physical activity than their healthy peers. The Canadian 24-h Movement Guidelines recommend children take part…
Abstract Number: 0470 • ACR Convergence 2020
Th1 Polarization Defines the T Cell Compartment in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients
Amelie Jule¹, Kacie Hoyt¹, Kevin Wei², Siobhan Case³, Margaret Chang¹, Ezra Cohen¹, Fatma Dedeoglu¹, Melissa Hazen¹, Jonathan Hausmann⁴, Olha Halyabar⁵, Erin Janssen⁵, Pui Lee⁶, Jeffrey Lo¹, Mindy Lo¹, Esra Meidan⁷, Jordan Roberts¹, Mary Beth Son¹, Robert Sundel⁵, Talal Chatila¹, Peter Nigrovic⁸ and Lauren Henderson⁹, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵Children's Hospital/Boston Medical Center, Boston, MA, ⁶1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA, ⁷Boston Children's Hospital, Somerville, MA, ⁸Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁹Boston Children's Hospital, Watertown, MA
Background/Purpose: Oligoarticular juvenile idiopathic arthritis (oligo JIA) is defined by limited joint involvement at disease onset. Some children achieve long-term remission while others continue to…
Abstract Number: 0728 • ACR Convergence 2020
Clinical Outcomes of Juvenile Arthritis in Adulthood: A Systematic Review
Lily Siok Hoon Lim¹, Woo Jin Kim², Yushi Wang² and Kaien Gu³, ¹University of Manitoba, Children's Hospital of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba Max Rady College of Medicine, Winnipeg, MB, Canada, ³University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Juvenile arthritis (JA) is the most common pediatric rheumatic disease, with potentially permanent functional impacts on patients long after initial diagnosis. Little is known…
Abstract Number: 1495 • ACR Convergence 2020
Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
Hermine I Brunner¹, Jonathan Akikusa², Eslam Al-Abadi², John Bohnsack³, Alina Lucica Boteanu², Gaelle Chedeville⁴, Ruben Cuttica², Wendy De La Pena⁴, Lawrence Jung⁴, Ozgur Kasapcopur², Katarzyna Kobusinska², Grant Schulert¹, Claudia Neiva², Rafael Rivas-Chacon⁴, Juan Cruz Rizo Rodriguez², Monica Vazquez-Del Mercado², Linda Wagner-Weiner⁴, Jennifer E Weiss¹, Carine Wouters², Ricardo M Suehiro⁵, Holly Posner⁶, Ann Wouters⁶, Keith S Kanik⁷, Zhen Luo⁸, Alberto Martini², Daniel J Lovell¹ and Nicolino Ruperto², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁴PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Shanghai, China (People's Republic)
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. We report the safety, tolerability, and efficacy of tofacitinib in patients (pts)…
Abstract Number: 0710 • ACR Convergence 2020
Early Start of Biological Treatment in Juvenile Idiopathic Arthritis: Does a Therapeutic Window Exist in Real Life?
Alina Lucica Boteanu¹, Andrea Briones-Figueroa², Laura Calvo-Sanz², África Andreu Suárez² and Antía García-Fernández², ¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: Data about when is the best moment to start BT in Juvenile Idiopathic Arthritis (JIA) patients and the impact of this prompt initiation are…
Abstract Number: 0729 • ACR Convergence 2020
Morbidity of JIA-associated Uveitis: Half of Patients Despite Systemic Treatment Still Show Ocular Damage During a Long-term Follow-up
Francesca Minoia¹, Luca Marelli², Gisella Beatrice Beretta³, Micol Romano⁴, Elisabetta Miserocchi⁴, Chiara Mapelli³, Antonella Petaccia³, Stefano Lanni³, Irene Pontikaki⁴, Giovanni Filocamo³ and Rolando Cimaz⁵, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ²San Giuseppe Hospital, IRCCS Multimedica, Milan, Italy, Milan, Italy, ³Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ⁴ASST Gaetano Pini-CTO Institute, Milan, Italy, Milan, Italy, ⁵ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy
Background/Purpose: Uveitis is the most common extra-articular complication of juvenile Idiopathic arthritis (JIA). Due to its typical indolent and chronic course, children with this condition…
Abstract Number: 1616 • ACR Convergence 2020
Systematic Review of Effectiveness Outcomes Reported in Rheumatology Transition Literature
Heather Bannerman¹, Karen Beattie¹, Avanti Patel², Milica Tanic², Michelle Batthish³ and Mark Matsos², ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: In young patients with rheumatologic disease, transition from pediatric to adult care is a complex process. Poor transitional care leads to health deterioration, loss…
Abstract Number: 0711 • ACR Convergence 2020
Alternative Dosing of Biologic Therapies Is Frequent Among Children with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Colleen Correll¹, Peter Shrader², Anne Dennos³, Thomas Phillips², Natalie Shiff⁴, Ruud Verstegen⁵ and Timothy Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Duke University, Durham, ³Duke University, Durham, NC, ⁴Florida, Gainesville, FL, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic agents are integral to the treatment of juvenile idiopathic arthritis (JIA) and associated uveitis. Pediatric rheumatologists may increase the dosage of biologics beyond…
Abstract Number: 0730 • ACR Convergence 2020
To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?
Maria Teran¹, Alina Lucica Boteanu², Carlos Guillen¹, Cristina Pijoan¹, Jose Quinones¹, Veronica Garcia³, Ivan Del Bosque-Granero³, Laura Calvo-Sanz⁴ and Mónica Vázquez⁴, ¹Hospital Ramon y Cajal, Madrid, Madrid, Spain, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: To determine the association between the occurrence of uveitis flares in patients with Juvenile Idiopathic Arthritis (JIA) and the de-intensification of immunosuppressive treatment.Methods: We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.